<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502281</url>
  </required_header>
  <id_info>
    <org_study_id>05/2006e</org_study_id>
    <nct_id>NCT00502281</nct_id>
  </id_info>
  <brief_title>Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients</brief_title>
  <official_title>Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <brief_summary>
    <textblock>
      At the present the first options to induce ovulation in polycystic ovary syndrome with&#xD;
      anovulatory infertility are clomiphene citrate (CC) and metformin. Notwithstanding the&#xD;
      effectiveness of CC and metformin alone or in a sequential or combined regimen, a percentage&#xD;
      of patients ranging from 5% to 30% remain anovulatory. For these patients, the use of&#xD;
      gonadotropins for controlled ovarian stimulation (COS) is indicated.&#xD;
&#xD;
      Moreover, to date it isn't clear if COS should be followed by timed intercourse (TI) or&#xD;
      intrauterine insemination (IUI).&#xD;
&#xD;
      The aim of the present study will be to compare TI and IUI in infertile PCOS patients&#xD;
      undergoing COS in terms of cost-benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infertile PCOS patients who remain anovulatory after CC or metformin treatment will be&#xD;
      enrolled. All patients will receive gonadotropins in low-dose step-up protocol for COS, and&#xD;
      randomized to receive three trials of TI (group A) or IUI (group B).&#xD;
&#xD;
      All patients eligible will undergo baseline assessment consisting of anthropometric,&#xD;
      hormonal, and ultrasonographic evaluations.&#xD;
&#xD;
      In all patients the COS will be obtained using highly purified urinary FSH in a low-dose&#xD;
      step-up protocol, and both TI and IUI will be performed after 35 hours from ovulation&#xD;
      induction with human chorionic gonadotropin.&#xD;
&#xD;
      During the study, the clinical and reproductive outcomes, the adverse experience will be&#xD;
      evaluated in each patient.&#xD;
&#xD;
      Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less&#xD;
      will be considered significant. Continuous variables will be analyzed with the unpaired t&#xD;
      test and general linear model for repeated measures analysis with Bonferroni test for the&#xD;
      post-hoc analysis as required. For categorical variables, the Pearson chi-square and Fisher's&#xD;
      exact tests will be used. Cumulative pregnancy rate, our primary end-point, will be&#xD;
      calculated by the Kaplan-Maier method, and the differences between the two groups will be&#xD;
      assessed with the log-rank test. Cox proportional-hazards model will be used to calculate the&#xD;
      hazard ratio for new pregnancy in both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COS followed by TI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COS followed by IUI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>highly purified urinary FSH</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>timed intercourses, intrauterine insemination</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome (using NIH criteria)&#xD;
&#xD;
          -  Anovulatory infertility (using WHO criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or &gt;35 years&#xD;
&#xD;
          -  Severe obesity (BMI &gt;35)&#xD;
&#xD;
          -  Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent&#xD;
             medical illnesses&#xD;
&#xD;
          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital&#xD;
             adrenal hyperplasia&#xD;
&#xD;
          -  Current or previous (within the last six months) use of oral contraceptives,&#xD;
             glucocorticoids, antiandrogens, anti-obesity drugs, hormonal drugs&#xD;
&#xD;
          -  Intention to start a diet or a specific program of physical activity&#xD;
&#xD;
          -  Organic pelvic diseases&#xD;
&#xD;
          -  Previous pelvic surgery&#xD;
&#xD;
          -  Suspected peritoneal factor infertility&#xD;
&#xD;
          -  Tubal or male factor infertility or sub-fertility&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University &quot;Magna Graecia&quot; of Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Orio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, University &quot;Federico II&quot; of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achille Tolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University &quot;Federico II&quot; of Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pugliese Hospital</name>
      <address>
        <city>Catanzaro</city>
        <state>Catanzaro, CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Stefano Palomba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gonadotropins</keyword>
  <keyword>Infertility</keyword>
  <keyword>Intrauterine insemination</keyword>
  <keyword>PCOS</keyword>
  <keyword>Timed intercourse</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

